866-997-4948(US-Canada Toll Free)

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 112 Pages

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Pipeline Review, H2 2017

Summary

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6-Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 14 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Melanoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colon Tumor, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Fallopian Tube Cancer, Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Inflammation, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Myelodysplastic Syndrome, Neuroblastoma, Neurodegenerative Diseases, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thyroid Cancer.

Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Overview 9
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 17
Products under Development by Universities/Institutes 24
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Therapeutics Assessment 26
Assessment by Mechanism of Action 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 31
Celgene Corp 31
Chong Kun Dang Pharmaceutical Corp 32
Curis Inc 33
HitGen LTD 33
Kancera AB 34
Karus Therapeutics Ltd 34
Medivir AB 35
Merck & Co Inc 35
Millennium Pharmaceuticals Inc 36
OnKure Inc 37
Quimatryx SL 37
Shuttle Pharmaceuticals LLC 37
Sigma-Tau SpA 38
SK Biopharmaceuticals Co Ltd 38
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Drug Profiles 39
ACY-1083-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ACY-738-Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ACY-775-Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
C-1A-Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
citarinostat-Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CKD-504-Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
CKD-506-Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CKD-509-Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CKD-L-Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CUDC-907-Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
HG-3001-Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
IKH-12-Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
KA-2507-Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
KAN-0439221-Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
KAN-0439782-Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
MPT-0B291-Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Nexturastat A-Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ONCO-101-Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
QTX-125-Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
QTX-153-Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
remetinostat-Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ricolinostat-Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma-Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease-Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to Inhibit HDAC6 for Oncology-Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders-Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Small Molecule to Inhibit HDAC6 for Sepsis-Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Pancreatic Cancer and Charcot-Marie-Tooth Disease-Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecules to Inhibit HDAC6 for Colorectal Cancer-Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases-Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecules to Inhibit HDAC6 for Oncology-Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecules to Inhibit HDAC6 for Oncology and Immunology-Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology-Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
SP-259-Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
ST-3595-Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Synthetic Peptides to Inhibit HDAC6 for Oncology-Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
vorinostat-Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Dormant Products 96
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)-Product Development Milestones 99
Featured News & Press Releases 99
Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial 99
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 99
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 99
Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model 100
Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma 101
Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting 102
Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting 103
Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting 104
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 105
Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 106
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 107
Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 107
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 108
Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 109
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112

List of Tables
Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Indications, H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Products under Development by Companies, H2 2017 18
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23
Number of Products under Investigation by Universities/Institutes, H2 2017 24
Products under Investigation by Universities/Institutes, H2 2017 25
Number of Products by Stage and Mechanism of Actions, H2 2017 26
Number of Products by Stage and Route of Administration, H2 2017 28
Number of Products by Stage and Molecule Type, H2 2017 30
Pipeline by Celgene Corp, H2 2017 31
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 32
Pipeline by Curis Inc, H2 2017 33
Pipeline by HitGen LTD, H2 2017 34
Pipeline by Kancera AB, H2 2017 34
Pipeline by Karus Therapeutics Ltd, H2 2017 35
Pipeline by Medivir AB, H2 2017 35
Pipeline by Merck & Co Inc, H2 2017 36
Pipeline by Millennium Pharmaceuticals Inc, H2 2017 36
Pipeline by OnKure Inc, H2 2017 37
Pipeline by Quimatryx SL, H2 2017 37
Pipeline by Shuttle Pharmaceuticals LLC, H2 2017 38
Pipeline by Sigma-Tau SpA, H2 2017 38
Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017 38
Dormant Products, H2 2017 96
Dormant Products, H2 2017 (Contd..1), H2 2017 97
Dormant Products, H2 2017 (Contd..2), H2 2017 98

List of Figures
Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Top 10 Indications, H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 26
Number of Products by Routes of Administration, H2 2017 27
Number of Products by Stage and Routes of Administration, H2 2017 27
Number of Products by Molecule Types, H2 2017 29
Number of Products by Stage and Molecule Types, H2 2017 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *